The French specialist in natural raw materials for perfumery, cosmetics, and aromas strengthens its partnership with the Italian biotechnology company through an investment in a joint venture.

With this enhanced partnership, Robertet aims to consolidate its position in the cosmetic active ingredients market. The aim of this very first step in biotech, is to bring together Aethera Biotech’s technologies — its intellectual property, production capabilities and existing product line — with the global commercial reach of Robertet.

Founded in 2016, Aethera Biotech specializes in the research, development and production of active ingredients from cell multiplication process. A subsidiary of the Italian family-owned group Cereal Docks, Aethera Biotech is a pioneer in phyto-complex biotechnologies. Inspired by natural plant mechanisms, this technology enables the secure production of natural extracts in controlled conditions, independent of climatic, agricultural or geopolitical constraints, while significantly reducing environmental impact. Based in Camisano Vicentino, Aethera Biotech employs a team of 25 professionals with complementary expertise, covering all biotech functions from R&D to industrialization.

Aethera Biotech will become Robertet’s center of excellence for future biotech developments across the Group, enabling it to enter the market for topical cosmetic active ingredients, with a unique and innovative portfolio.

“This joint venture reflects our conviction that biotech will play an increasingly important role in the development of high-value, sustainable solutions. It supports our ambition to reinforce our leadership in naturals while opening new pathways for innovation and growth for our customers,” explains Jérôme Bruhat, Chief Executive Officer of Robertet.

“After nearly two years of close collaboration, this next step further advances our vision of Augmented Naturality,” adds Olivier Maubert, Group Innovation Director and Head of the Health & Beauty division at Robertet.

Robertet’s progressive investment in the joint venture will be completed in two phases over a three-year period under certain conditions.